Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease

Author： Roberts Rebecca L   Gearry Richard B   Kennedy Martin A   Barclay Murray L  

Publisher： Future Medicine

ISSN： 1741-0541

Source： Personalized Medicine, Vol.5, Iss.3, 2008-05, pp. : 233-248

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 5, 2015-03 ,pp. : 494-495

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors associated with thiopurine non‐adherence in patients with inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1097-1108

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease

By  

Nephron Clin Pract, Vol. 119, Iss. 2, 2011-06 ,pp. : c89-c96

Karger

Access to resources Recommend Favorite

Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1025-1037

John Wiley & Sons Inc

Access to resources Recommend Favorite

Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 259-270

John Wiley & Sons Inc

Access to resources Recommend Favorite